JP2022519341A5 - - Google Patents

Info

Publication number
JP2022519341A5
JP2022519341A5 JP2021539922A JP2021539922A JP2022519341A5 JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5 JP 2021539922 A JP2021539922 A JP 2021539922A JP 2021539922 A JP2021539922 A JP 2021539922A JP 2022519341 A5 JP2022519341 A5 JP 2022519341A5
Authority
JP
Japan
Application number
JP2021539922A
Other languages
Japanese (ja)
Other versions
JP7606706B2 (ja
JPWO2020144697A5 (https=
JP2022519341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/050047 external-priority patent/WO2020144697A1/en
Publication of JP2022519341A publication Critical patent/JP2022519341A/ja
Publication of JPWO2020144697A5 publication Critical patent/JPWO2020144697A5/ja
Publication of JP2022519341A5 publication Critical patent/JP2022519341A5/ja
Priority to JP2024213235A priority Critical patent/JP7788118B2/ja
Application granted granted Critical
Publication of JP7606706B2 publication Critical patent/JP7606706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539922A 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体 Active JP7606706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213235A JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791808P 2019-01-13 2019-01-13
US62/791,808 2019-01-13
PCT/IL2020/050047 WO2020144697A1 (en) 2019-01-13 2020-01-13 Antibodies specific to human nectin-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213235A Division JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Publications (4)

Publication Number Publication Date
JP2022519341A JP2022519341A (ja) 2022-03-23
JPWO2020144697A5 JPWO2020144697A5 (https=) 2023-01-20
JP2022519341A5 true JP2022519341A5 (https=) 2023-01-20
JP7606706B2 JP7606706B2 (ja) 2024-12-26

Family

ID=69701225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539922A Active JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Country Status (9)

Country Link
US (1) US12545727B2 (https=)
EP (1) EP3908372A1 (https=)
JP (2) JP7606706B2 (https=)
KR (1) KR20210117277A (https=)
CN (2) CN118878685A (https=)
AU (1) AU2020207664B2 (https=)
CA (1) CA3125962A1 (https=)
IL (1) IL284807B2 (https=)
WO (1) WO2020144697A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023161943A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies against nectin-2 and drug conjugates thereof
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN121752593A (zh) 2023-05-23 2026-03-27 肿瘤研究所基金会 靶向黏附素2(cd112)和psma的单特异性和双特异性抗体以及抗体-药物缀合物
WO2024240899A1 (en) 2023-05-23 2024-11-28 Universite De Geneve Dual targeting of psma and nectin2 in prostate cancer
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
KR20250161707A (ko) 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도
KR20250161706A9 (ko) 2024-05-08 2026-02-03 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 항체 및 이의 용도
KR20250175021A (ko) * 2024-06-05 2025-12-16 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20090142346A1 (en) 2005-10-07 2009-06-04 Takeda Pharmaceutical Company Limited Preventive/Remedy for Cancer
CA2666249A1 (en) 2006-10-06 2008-04-17 Takeda Pharmaceutical Company Limited Agent for preventing/treating cancer
WO2008126847A1 (ja) 2007-04-11 2008-10-23 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
PL2800196T3 (pl) 2011-12-27 2019-05-31 Lg Chemical Ltd Litowa bateria akumulatorowa i sposób jej wytwarzania
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
EP3344657A1 (en) * 2015-09-02 2018-07-11 The Regents of the University of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
JP2018534245A (ja) 2015-09-14 2018-11-22 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
EP3448875A4 (en) 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
AU2017355218B2 (en) * 2016-11-02 2024-02-22 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
WO2023161943A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies against nectin-2 and drug conjugates thereof

Similar Documents

Publication Publication Date Title
JP2022519341A5 (https=)
JPWO2021229807A1 (https=)
CN306236390S (https=)
CN305746792S (https=)
CN305536845S (https=)
CN305536829S (https=)
CN305536644S (https=)
CN305535615S (https=)
CN305534849S (https=)
CN305533827S (https=)
CN305532581S (https=)
CN305649225S (https=)
CN305531956S (https=)
CN305531268S (https=)
CN305531126S (https=)
CN305530635S (https=)
CN305527652S (https=)
CN305527360S (https=)
CN305746351S (https=)
CN306994318S (https=)
CN306245103S (https=)
CN305703361S (https=)
CN305696499S (https=)
CN305665517S (https=)
CN306244535S (https=)